Advertisement

Hallucinations, Delusions and Impulse Control Disorders in Parkinson Disease

  • Karlo J. Lizarraga
    Correspondence
    Corresponding author. 399 Bathurst Street, McL 7-412, Toronto, Ontario, M5T 2S8, Canada.
    Affiliations
    The Edmond J. Safra Program in Parkinson Disease and the Morton and Gloria Shulman Movement Disorders Clinic, Division of Neurology, Department of Medicine, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada

    University of Toronto, Toronto, Ontario, Canada

    Krembil Research Institute, Toronto, Ontario, Canada

    Motor Physiology and Neuromodulation Program, Division of Movement Disorders, Department of Neurology, University of Rochester, Rochester, New York, United States

    Center for Health + Technology (CHeT), University of Rochester, Rochester, New York, United States
    Search for articles by this author
  • Susan H. Fox
    Affiliations
    The Edmond J. Safra Program in Parkinson Disease and the Morton and Gloria Shulman Movement Disorders Clinic, Division of Neurology, Department of Medicine, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada

    University of Toronto, Toronto, Ontario, Canada

    Krembil Research Institute, Toronto, Ontario, Canada
    Search for articles by this author
  • Antonio P. Strafella
    Affiliations
    The Edmond J. Safra Program in Parkinson Disease and the Morton and Gloria Shulman Movement Disorders Clinic, Division of Neurology, Department of Medicine, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada

    University of Toronto, Toronto, Ontario, Canada

    Krembil Research Institute, Toronto, Ontario, Canada
    Search for articles by this author
  • Anthony E. Lang
    Affiliations
    The Edmond J. Safra Program in Parkinson Disease and the Morton and Gloria Shulman Movement Disorders Clinic, Division of Neurology, Department of Medicine, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada

    University of Toronto, Toronto, Ontario, Canada

    Krembil Research Institute, Toronto, Ontario, Canada
    Search for articles by this author
Published:October 17, 2019DOI:https://doi.org/10.1016/j.cger.2019.09.004

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Clinics in Geriatric Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Obeso J.A.
        • Stamelou M.
        • Goetz C.G.
        • et al.
        Past, present, and future of Parkinson’s disease: a special essay on the 200th anniversary of the shaking palsy.
        Mov Disord. 2017; 32: 1264-1310
        • Weintraub D.
        • Burn D.
        Parkinson’s disease: the quintessential neuropsychiatric disorder.
        Mov Disord. 2011; 26: 1022-1031
        • Marras C.
        • Beck J.C.
        • Bower J.H.
        • et al.
        Prevalence of Parkinson’s disease across North America.
        NPJ Parkinsons Dis. 2018; 4: 21
        • Levy G.
        The relationship of Parkinson disease with aging.
        Arch Neurol. 2007; 64: 1242-1246
        • Seppi K.
        • Ray Chaudhuri K.
        • Coelho M.
        • et al.
        Update on treatments of nonmotor symptoms of Parkinson’s disease-an evidence-based medicine review.
        Mov Disord. 2019; 34: 180-198
        • Weintraub D.
        • David A.S.
        • Evans E.H.
        • et al.
        Clinical spectrum of impulse control disorders in Parkinson’s disease.
        Mov Disord. 2015; 30: 121-127
        • Ravina B.
        • Marder K.
        • Fernandez H.H.
        • et al.
        Diagnostic criteria for psychosis in Parkinson’s disease: report of an NINDS, NIMH work group.
        Mov Disord. 2007; 22: 1061-1068
        • Fenelon G.
        • Soulas T.
        • Zenasni F.
        • et al.
        The changing face of Parkinson’s disease-associated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria.
        Mov Disord. 2010; 25: 763-766
        • Coebergh J.A.
        • Lauw R.F.
        • Bots R.
        • et al.
        Musical hallucinations: review of treatment effects.
        Front Psychol. 2015; 6: 814
        • Goetz C.G.
        • Stebbins G.T.
        • Ouyang B.
        Visual plus nonvisual hallucinations in Parkinson’s disease: development and evolution over 10 years.
        Mov Disord. 2011; 26: 2196-2200
        • Arnulf I.
        • Bonnet A.-M.
        • Damier P.
        • et al.
        Hallucinations, REM sleep, and Parkinson’s disease: a medical hypothesis.
        Neurology. 2000; 55: 281-288
        • Christodoulou G.N.
        • Margariti M.
        • Kontaxakis V.P.
        • et al.
        The delusional misidentification syndromes: strange, fascinating, and instructive.
        Curr Psychiatry Rep. 2009; 11: 185-189
        • Thomsen T.R.
        • Panisset M.
        • Suchowersky O.
        • et al.
        Impact of standard of care for psychosis in Parkinson disease.
        J Neurol Neurosurg Psychiatry. 2008; 79: 1413-1415
        • Rudolph J.L.
        • Salow M.J.
        • Angelini M.C.
        • et al.
        The anticholinergic risk scale and anticholinergic adverse effects in older persons.
        Arch Intern Med. 2008; 168: 508-513
        • Rabinak C.
        • Nirenberg M.
        Dopamine agonist withdrawal syndrome in Parkinson disease.
        Arch Neurol. 2010; 67: 58-63
        • Parkinson Study Group
        Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease.
        N Engl J Med. 1999; 340: 757-763
        • Pollak P.
        • Tison F.
        • Rascol O.
        • et al.
        Clozapine in drug induced psychosis in Parkinson’s disease: a randomized, placebo controlled study with open follow up.
        J Neurol Neurosurg Psychiatry. 2004; 75: 689-695
        • van Eijk M.M.
        • Roes K.C.
        • Honing M.L.
        • et al.
        Effect of rivastigmine as an adjunct to usual care with haloperidol on duration of delirium and mortality in critically ill patients: a multicenter, double-blind, placebo-controlled randomized trial.
        Lancet. 2010; 376: 1829-1837
        • Chen S.
        • Shi L.
        • Liang F.
        • et al.
        Exogenous melatonin for delirium prevention: a meta-analysis of randomized controlled trials.
        Mol Neurobiol. 2016; 53: 4046-4053
        • Pagonabarraga J.
        • Martinez-Horta S.
        • Fernandez de Bobadilla R.
        • et al.
        Minor hallucinations occur in drug-naive Parkinson’s disease patients, even from the premotor phase.
        Mov Disord. 2016; 31: 45-52
        • Forsaa E.
        • Larsen J.
        • Wentzel-Larsen T.
        • et al.
        A 12-year population-based study of psychosis in Parkinson disease.
        Arch Neurol. 2010; 67: 996-1001
        • McKinlay A.
        • Grace R.
        • Dalrymple-Alford J.
        • et al.
        A profile of neuropsychiatric problems and their relationship to quality of life for Parkinson’s disease patients without dementia.
        Parkinsonism Relat Disord. 2008; 14: 37-42
        • Forsaa E.
        • Larsen J.
        • Wentzel-Larsen T.
        • et al.
        What predicts mortality in Parkinson disease? A prospective population-based long-term study.
        Neurology. 2010; 75: 1270-1276
        • Factor S.
        • Feustel P.
        • Freidman J.
        • et al.
        Longitudinal outcome of Parkinson’s disease patients with psychosis.
        Neurology. 2003; 60: 1756-1761
        • Aarsland D.
        • Larsen J.
        • Cummings J.
        • et al.
        Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study.
        Arch Neurol. 1999; 56: 595-601
        • Marsh L.
        • Williams J.
        • Rocco M.
        • et al.
        Psychiatric comorbidities in patients with Parkinson disease and psychosis.
        Neurology. 2004; 63: 293-300
        • Pacchetti C.
        • Manni R.
        • Zangaglia R.
        • et al.
        Relationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinson’s disease.
        Mov Disord. 2005; 20: 1439-1448
        • Rascol O.
        • Brooks D.J.
        • Korczyn A.D.
        • et al.
        A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa.
        N Engl J Med. 2000; 342: 1484-1491
        • Parkinson Study Group CALM Cohort Investigators
        Long-term effect of initiating pramipexole vs. levodopa in early Parkinson disease.
        Arch Neurol. 2009; 66: 563-570
        • Goetz C.G.
        • Pappert E.J.
        • Blasucci L.M.
        • et al.
        Intravenous levodopa in hallucinating Parkinson’s disease patients: high-dose challenge does not precipitate hallucinations.
        Neurology. 1998; 50: 515-517
        • Olanow C.
        • Stern M.
        • Sethi K.
        The scientific and clinical basis of the treatment of Parkinson disease.
        Neurology. 2009; 72: S1-S136
        • Borgemeester R.W.
        • Lees A.J.
        • van Laar T.
        Parkinson’s disease, visual hallucinations and apomorphine: a review of the available evidence.
        Parkinsonism Relat Disord. 2016; 27: 35-40
        • Manson A.J.
        • Hanagasi H.
        • Turner K.
        • et al.
        Intravenous apomorphine therapy in Parkinson’s disease: clinical and pharmacokinetic observations.
        Brain. 2001; 124: 331-340
        • Bergman J.
        • Lerner V.
        Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson’s disease.
        Clin Neuropharmacol. 2002; 25: 107-110
        • Alvir J.M.
        • Lieberman J.A.
        • Safferman A.Z.
        • et al.
        Clozapine-induced agranulocytosis. Incidence and risk factors in the United States.
        N Engl J Med. 1993; 329: 162-167
        • Shah A.A.
        • Aftab A.
        • Coverdale J.
        QTc prolongation with antipsychotics: is routine ECG monitoring recommended?.
        J Psychiatr Pract. 2014; 20: 196-206
        • The French Clozapine Parkinson Study Group
        Clozapine in drug-induced psychosis in Parkinson’s disease.
        Lancet. 1999; 353: 2041-2042
        • Weintraub D.
        • Chen P.
        • Ignacio R.
        • et al.
        Patterns and trends in antipsychotic prescribing for Parkinson disease psychosis.
        Arch Neurol. 2011; 68: 899-904
        • Honigfeld G.
        • Arellano F.
        • Sethi J.
        • et al.
        Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry.
        J Clin Psychiatry. 1998; 59: 3-7
        • Yaw T.K.
        • Fox S.H.
        • Lang A.E.
        Clozapine in Parkinsonian rest tremor: a review of outcomes, adverse reactions, and possible mechanisms of action.
        Mov Disord Clin Pract. 2015; 3: 116-124
        • Ondo W.
        • Tintner R.
        • Voung K.
        • et al.
        Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson’s disease.
        Mov Disord. 2005; 20: 958-963
        • Rabey J.
        • Prokhorov T.
        • Miniovitz A.
        • et al.
        Effect of quetiapine in psychotic Parkinson’s disease patients: a double-blind labeled study of 3 months’ duration.
        Mov Disord. 2007; 22: 313-318
        • Shotbolt P.
        • Samuel M.
        • Fox C.
        • et al.
        A randomized controlled trial of quetiapine for psychosis in Parkinson’s disease.
        Neuropsychiatr Dis Treat. 2009; 5: 327-332
        • Cummings J.
        • Isaacson S.
        • Mills R.
        • et al.
        Pimavanserin for patients with Parkinson’s disease psychosis: a randomized, placebo-controlled phase 3 trial.
        Lancet. 2014; 383: 533-540
        • Schubmehl S.
        • Sussman J.
        Perspective on pimavanserin and the SASP-PD: novel scale development as a means to FDA approval.
        Am J Geriatr Psychiatry. 2018; 26: 1007-1011
        • Friedman J.H.
        • Factor S.A.
        Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson’s disease.
        Mov Disord. 2000; 15: 201-211
        • Weintraub D.
        • Chiang C.
        • Kim H.M.
        • et al.
        Association of antipsychotic use with mortality risk in patients with Parkinson disease.
        JAMA Neurol. 2016; 73: 535-541
        • Voon V.
        • Fox S.
        Medication-related impulse control and repetitive behaviors in Parkinson disease.
        Arch Neurol. 2007; 64: 1089-1096
        • Weintraub D.
        • Papay K.
        • Siderowf A.
        • et al.
        Screening for impulse control disorder symptoms in patients with de novo Parkinson disease: a case-control study.
        Neurology. 2013; 80: 176-180
        • Weintraub D.
        • Koester J.
        • Potenza M.
        • et al.
        Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients.
        Arch Neurol. 2010; 67: 589-595
        • Corvol J.C.
        • Artaud F.
        • Cormier-Dequaire F.
        • et al.
        Longitudinal analysis of impulse control disorders in Parkinson disease.
        Neurology. 2018; 91: e189-e201
        • Biundo R.
        • Weis L.
        • Abbruzzese G.
        • et al.
        Impulse control disorders in advanced Parkinson’s disease with dyskinesia: the ALTHEA study.
        Mov Disord. 2017; 32: 1557-1565
        • Papay K.
        • Mamikonyan E.
        • Siderowf A.
        • et al.
        Patient versus informant reporting ICD symptoms in Parkinson’s disease using the QUIP: validity and variability.
        Parkinsonism Relat Disord. 2011; 17: 153-155
        • Rizos A.
        • Sauerbier A.
        • Antonini A.
        • et al.
        A European multicentre survey of impulse control behaviours in Parkinson’s disease patients treated with short- and long-acting dopamine agonists.
        Eur J Neurol. 2016; 23: 1255-1261
        • Bastiaens J.
        • Dorfman B.J.
        • Christos P.J.
        • et al.
        Prospective cohort study of impulse control disorders in Parkinson’s disease.
        Mov Disord. 2013; 28: 327-333
        • Cornelius J.
        • Tippmann-Peikert M.
        • Slocumb N.
        • et al.
        Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study.
        Sleep. 2010; 33: 81-87
        • Weintraub D.
        • Sohr M.
        • Potenza M.
        • et al.
        Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study.
        Ann Neurol. 2010; 68: 963-968
        • Carriere N.
        • Kreisler A.
        • Dujardin K.
        • et al.
        Impulse control disorders in Parkinson’s disease: a cohort of 35 patients.
        Rev Neurol (Paris). 2012; 168: 143-151
        • Voon V.
        • Sohr M.
        • Lang A.
        • et al.
        Impulse control disorders in Parkinson disease: a multicenter case-control study.
        Ann Neurol. 2011; 69: 986-996
        • Miyasaki J.
        • Hassan K.
        • Lang A.
        • et al.
        Punding prevalence in Parkinson’s disease.
        Mov Disord. 2007; 22: 1179-1181
        • Evans A.
        • Katzenschlager R.
        • Paviour D.
        • et al.
        Punding in Parkinson’s disease: its relation to the dopamine dysregulation syndrome.
        Mov Disord. 2004; 19: 397-405
        • Cilia R.
        • Siri C.
        • Canesi M.
        • et al.
        Dopamine dysregulation syndrome in Parkinson’s disease: from clinical and neuropsychological characterization to management and long-term outcome.
        J Neurol Neurosurg Psychiatry. 2014; 85: 311-318
        • Mamikonyan E.
        • Siderowf A.
        • Duda J.
        • et al.
        Long-term follow-up of impulse control disorders in Parkinson’s disease.
        Mov Disord. 2008; 23: 75-80
        • Martinez-Martin P.
        • Reddy P.
        • Katzenschlager R.
        • et al.
        EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson’s disease.
        Mov Disord. 2015; 30: 510-516
        • Thomas A.
        • Bonnani L.
        • Gambi F.
        • et al.
        Pathological gambling in Parkinson disease is reduced by amantadine.
        Ann Neurol. 2010; 68: 400-404